Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × tucatinib × 30 days × Clear all

Phase

Phase 2 8 Phase 3 2 Phase EARLY_PHASE1 1 Phase 2/3 1 Phase 1/2 1 Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

HER2-positive Breast Cancer 1

Interventions

Magnetic Resonance Spectroscopy 12 Cisplatin 12 Specimen Handling 10 Doxorubicin 9 Carboplatin 9 Nivolumab 7 pembrolizumab 6 Radiotherapy 6 Platinum 6 Paclitaxel 6 Gemcitabine 6 Bevacizumab 6 1,2-diaminocyclohexaneplatinum II citrate 6 atezolizumab 5 Radiation 5 Ipilimumab 5 venetoclax 4 Rituximab 4 Pemetrexed 4 Immunoglobulin G 4 Docetaxel 4 Disulfides 4 Cyclophosphamide 4 Biopsy 4 Vincristine 3 Taxes 3 Radiotherapy, Intensity-Modulated 3 Prednisone 3 Oxaliplatin 3 Methotrexate 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07413939 2026-03-10

BREnnA

Hoffmann-La Roche

Phase 2/3 Not yet recruiting

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡